Real-world treatment patterns and survival outcomes in men with metastatic castration-resistant prostate cancer in Finland: a national, population-based cohort study
DOI:
https://doi.org/10.2340/1651-226X.2025.42173Keywords:
Real-world evidence, prostate cancer, mCRPC, androgen receptor pathway inhibitors, treatment, overall survival, androgen receptor antagonistsAbstract
Background: Metastatic castration-resistant prostate cancer (mCRPC) treatment is advancing yet Nordic, real-world evidence for its use is scarce. In this population-based cohort study, we describe characteristics of patients with mCRPC, and their treatment patterns and survival outcomes in Finland.
Methods: Incident patients with mCRPC diagnosed during 2013–2021 were identified from data lakes in two large and representative, Finnish hospital districts, and linked to data on drug purchases and causes of death from national registries.
Results: Of a total of 31,307 patients with prostate cancer, 2,475 progressed to mCRPC during 2013–2021. Those who received no life-prolonging treatment(s) (28% overall) were older with more comorbidities than treated patients. After 2018, the proportion of patients who received life-prolonging treatments increased from 61% to 80%. Of those who received treatment before androgen receptor pathway inhibitors (ARPIs) were reimbursed as first-line (1L) treatment for mCRPC in Finland, 68% received docetaxel, 19% abiraterone and 12% enzalutamide 1L; post-reimbursement, 4% received docetaxel, 24% abiraterone and 71% enzalutamide 1L. Median overall survival for treated patients with mCRPC was 28.3 (95% CI: 26.3–30.4) and 38.5 (95% CI: 32.7–42.1) months pre- and post-reimbursement of 1L-ARPIs, respectively.
Interpretation: The ARPI reimbursement status changes significantly influenced treatment patterns for mCRPC in Finland, favouring enzalutamide over docetaxel. This expanded the pool of men eligible for 1L treatment and improved overall survival by a median of 10 months. These findings highlight the importance of health policy decisions in shaping treatment strategies and patient outcomes in prostate cancer.
Downloads
References
Pitkäniemi JM, Malila NK, Heikkinen, S, Seppä, K. Cancer ni Finland in 2022 [Internet]. Finnish Cancer Registry. [cited 2024 Sep 11]. Availa-ble from: https://syoparekisteri.fi/assets/themes/ssy3/factsheets/syopa_2022_tilastoraportti.html
Nordcan. NORDCAN Factsheet Prostate Cancer Finland [Internet]. Nordcan; 2022 [updated 2022 Sep 2024 Sep 11]. Available from: https://gco.iarc.fr/media/nordcan/factsheets/92/en/countries/246/prostate-240-finland-246.pdf
Dong L, Zieren RC, Xue W, de Reijke TM, Pienta KJ. Metastatic prostate cancer remains incurable, why? Asian J Urol. 2019;6:26–41.
https://doi.org/10.1016/j.ajur.2018.11.005 DOI: https://doi.org/10.1016/j.ajur.2018.11.005
Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol. 2010;17(Suppl 2):S72–S79.
https://doi.org/10.3747/co.v17i0.718 DOI: https://doi.org/10.3747/co.v17i0.718
Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65:1180–1192.
https://doi.org/10.1111/j.1742-1241.2011.02799.x DOI: https://doi.org/10.1111/j.1742-1241.2011.02799.x
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 201310;368:138–148.
https://doi.org/10.1056/NEJMoa1209096 DOI: https://doi.org/10.1056/NEJMoa1209096
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemo-therapy. N Engl J Med. 2014;371:424–433.
https://doi.org/10.1056/NEJMoa1405095 DOI: https://doi.org/10.1056/NEJMoa1405095
Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castration sensitive prostate cancer. N Engl J Med. 2019;381:13–24.
https://doi.org/10.1056/NEJMoa1903307 DOI: https://doi.org/10.1056/NEJMoa1903307
Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386:1132–1142.
https://doi.org/10.1056/NEJMoa2119115 DOI: https://doi.org/10.1056/NEJMoa2119115
EAU. EAU Guidelines on Prostate Cancer – Uroweb [Internet]. [updated 2024; cited 2024 Sep 11]. Available from: https://uroweb.org/guidelines/prostate-cancer
Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treat-ment and follow-up. Ann Oncol. 2020;31:1119–1134.
https://doi.org/10.1016/j.annonc.2020.06.011 DOI: https://doi.org/10.1016/j.annonc.2020.06.011
Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore N, Loredo E, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 2022;1(9):EVIDoa2200043.
https://doi.org/10.1056/EVIDoa2200043 DOI: https://doi.org/10.1056/EVIDoa2200043
Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023;402:291–303.
https://doi.org/10.1016/S0140-6736(23)01055-3 DOI: https://doi.org/10.1016/S0140-6736(23)01055-3
Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, et al. Rucaparib or physician’s choice in metastatic prostate cancer. N Engl J Med. 2023;388:719–732.
https://doi.org/10.1056/NEJMoa2214676 DOI: https://doi.org/10.1056/NEJMoa2214676
Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN Jr, Yu EY, et al. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2022;23:362–373.
https://doi.org/10.1016/S1470-2045(21)00757-9 DOI: https://doi.org/10.1016/S1470-2045(21)00757-9
Freedland SJ, Davis M, Epstein AJ, Arondekar B, Ivanova JI. Real-world treatment patterns and overall survival among men with meta-static castration-resistant prostate cancer (mCRPC) in the US Medicare population. Prostate Cancer Prostatic Dis. 2024;27:327–333.
https://doi.org/10.1038/s41391-023-00725-8 DOI: https://doi.org/10.1038/s41391-023-00725-8
George DJ, Sartor O, Miller K, Saad F, Tombal B, Kalinovský J, et al. Treatment patterns and outcomes in patients with metastatic castra-tion-resistant prostate cancer in a real-world clinical practice setting in the United States. Clin Genitourin Cancer. 2020;18:284–294.
https://doi.org/10.1016/j.clgc.2019.12.019 DOI: https://doi.org/10.1016/j.clgc.2019.12.019
Storås AH, Tsuruda K, Fosså SD, Andreassen BK. Time trends in systemic treatment for patients with metastatic prostate cancer: a national cohort study. Acta Oncol. 2023;62:1716–1722.
https://doi.org/10.1080/0284186X.2023.2257876 DOI: https://doi.org/10.1080/0284186X.2023.2257876
Vigneswaran HT, Warnqvist A, Andersson TML, Leval A, Eklund M, Nordström T, et al. Real world treatment utilization patterns in patients with castration-resistant prostate cancer. Scand J Urol. 2021;55:299–306.
https://doi.org/10.1080/21681805.2021.1936626 DOI: https://doi.org/10.1080/21681805.2021.1936626
Leith A, Kim J, Ribbands A, Clayton E, Yang L, Ghate SR. Real-world treatment patterns in metastatic castration-resistant prostate cancer across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan. Adv Ther. 2022;39:2236–2255.
https://doi.org/10.1007/s12325-022-02073-w DOI: https://doi.org/10.1007/s12325-022-02073-w
Malangone-Monaco E, Li W, Noxon V, Jiang S, Amin S, Ghate S, et al. Real-world treatment patterns among patients with metastatic castration-resistant prostate cancer (mCRPC) in the US. JCO. 2022;40(Suppl 6):49. DOI: https://doi.org/10.1200/JCO.2022.40.6_suppl.049
https://doi.org/10.1200/JCO.2022.40.6_suppl.0
Shore ND, Laliberté F, Ionescu-Ittu R, Yang L, Mahendran M, Lejeune D, et al. Real-world treatment patterns and overall survival of pa-tients with metastatic castration-resistant prostate cancer in the US prior to PARP inhibitors. Adv Ther. 2021;38:4520–4540.
https://doi.org/10.1007/s12325-021-01823-6 DOI: https://doi.org/10.1007/s12325-021-01823-6
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152–160.
https://doi.org/10.1016/S1470-2045(14)71205-7 DOI: https://doi.org/10.1016/S1470-2045(14)71205-7
Chowdhury S, Bjartell A, Lumen N, Maroto P, Paiss T, Gomez-Veiga F, et al. Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer: the Prostate Cancer Registry. Target Oncol. 2020;15:301–315. DOI: https://doi.org/10.1007/s11523-020-00720-2
https:/
Bjartell A, Costa L, Kramer G, Zurawski B, Galli L, Werbrouck P, et al. Real-world treatment sequencing in patients with metastatic castra-tion-resistant prostate cancer: results from the Prospective, International, Observational Prostate Cancer Registry. Eur Urol Open Sci. 2022;45:12–22.
https://doi.org/10.1016/j.euros.2022.08.018 DOI: https://doi.org/10.1016/j.euros.2022.08.018
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Antti Rannikko, Olivia Hölsä, Trude Ågesen, Mattias Ekman, Riikka Mattila
This work is licensed under a Creative Commons Attribution 4.0 International License.
